MA
VRTX icon

MYDA Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

MYDA Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,000
Closed -$578K – 135
2018
Q3 		$578K Buy
+3,000
New +$534K 0.31% 80
2018
Q1 		– Sell
-10,000
Closed -$1.5M – 180
2017
Q4 		$1.5M Buy
+10,000
New +$1.48M 0.66% 42

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

MYDA Advisors's VRTX Position: Q4 2018 in Review

MYDA Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2018, closing a stake of 3,000 shares — an estimated $578K sold.

MYDA Advisors first reported a position in VRTX in Q4 2017 and held it in 2 quarters. The position peaked at $1.5M in Q4 2017. 705 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

  • MYDA Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • MYDA Advisors sold 3,000 Vertex Pharmaceuticals shares in Q4 2018, an estimated $578K.
  • MYDA Advisors first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • MYDA Advisors's Vertex Pharmaceuticals position peaked at $1.5M in Q4 2017.
  • 705 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on MYDA Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.